Clinical Trials Using Sorafenib Tosylate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sorafenib Tosylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 44
1 2 Next >

  • Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer

    This randomized phase III trial studies sorafenib tosylate and stereotactic radiosurgery (stereotactic body radiation therapy) to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic radiosurgery, also known as stereotactic body radiation therapy, uses focused, high-dose radiation to help shrink tumors. It is not yet known whether giving sorafenib tosylate together with stereotactic radiosurgery is more effective than sorafenib tosylate alone in treating liver cancer.
    Location: 39 locations

  • Everolimus and Sorafenib Tosylate in Treating Patients with Recurrent High-Grade Gliomas

    This phase I / II trial studies how well everolimus and sorafenib tosylate work in treating patients with fast growing and aggressive (high-grade) gliomas that have come back. Everolimus and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 18 locations

  • Sorafenib Tosylate following a Liver Transplant in Treating Patients with Liver Cancer

    This phase II trial studies how well sorafenib tosylate works following a liver transplant in treating patients with liver cancer. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib tosylate is effective in preventing cancer recurrence in high risk patients following liver transplantation.
    Location: 12 locations

  • Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer

    This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with thyroid cancer that has spread to other places in the body or cannot be removed by surgery and has not responded to treatment with radioactive iodine. Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent it from growing but it could also cause more side effects than sorafenib tosylate alone. It is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the same, or worse than sorafenib tosylate alone.
    Location: 17 locations

  • Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

    This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
    Location: 11 locations

  • Navitoclax and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Solid Tumors

    This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment (refractory). Navitoclax and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • Sorafenib Tosylate and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Breast Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with whole brain radiation therapy in treating patients with breast cancer that has spread to the brain. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib tosylate and whole-brain radiation therapy together may kill more tumor cells.
    Location: 6 locations

  • Enzalutamide with or without Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer

    This phase I / II trial studies the side effects and the best dose of enzalutamide when given with or without sorafenib tosylate and to see how well it works in treating patients with liver cancer (hepatocellular carcinoma) that has spread to other places in the body and usually cannot be cured or controlled with treatment. Enzalutamide binds to proteins called androgen receptors, which are found in hepatocellular carcinoma and this may keep tumor cells from growing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may also prevent the growth of new blood vessels that tumors need to grow. It is not yet known whether enzalutamide is more effective with or without sorafenib tosylate in treating patients with liver cancer.
    Location: 7 locations

  • Sorafenib and Cyclophosphamide / Topotecan in Patients With Relapsed and Refractory Neuroblastoma

    This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigators first need to find out the highest dose of sorafenib that can be given safely together with cyclophosphamide and topotecan. This is the first study to test giving these three drugs together and will help determine the highest dose of sorafenib that can safely be given together with cyclophosphamide and topotecan to patients with resistant / relapsed neuroblastoma.
    Location: 5 locations

  • An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

    The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. NOTE: Global recruitment is complete but enrollment is ongoing for the China sub-study. The Completion Date for the Primary Outcome Measure is expected in October 2018.
    Location: 3 locations

  • A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

    This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
    Location: 4 locations

  • An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

    The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC. In the fifth cohort, additional clinical data will be generated for Child-Pugh B subjects. A Cabozantinib Combination Cohort has been added to evaluate the safety and tolerability of nivolumab in combination with cabozantinib and nivolumab with ipilimumab in combination with cabozantinib.
    Location: 4 locations

  • Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

    This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
    Location: 4 locations

  • Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

    The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
    Location: 4 locations

  • Trial of TRC105 and Sorafenib in Patients With HCC

    The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2.
    Location: 5 locations

  • Risk Adapted Focal Proton Beam Radiation and / or Surgery in Participants with Low, Intermediate, and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    This phase II trial studies how well chemotherapy, surgery, and radiation therapy work in treating patients with newly diagnosed rhabdomyosarcoma that has spread to other parts of the body. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.
    Location: 3 locations

  • Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection

    This phase IV trial studies how well the Food and Drug Administration (FDA) approved drug, sorafenib tosylate, works in treating patients with advanced liver cancer and hepatitis C infection. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
    Location: 5 locations

  • Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia

    This randomized phase II trial studies how well azacitidine or decitabine work in epigenetic priming in patients with newly diagnosed acute myeloid leukemia. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Sapanisertib or Sorafenib Tosylate in Treating Patients with Advanced or Metastatic Liver Cancer

    This randomized phase I / II trial studies the side effects and best dose of sapanisertib and how well sapanisertib or sorafenib tosylate works in treating patients with that has spread to other places in the body. Sapanisertib and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.
    Location: 2 locations

  • Sorafenib Tosylate and Hydroxychloroquine Sulfate in Treating Patients with Advanced or Metastatic Liver Cancer

    This phase II trial studies how well sorafenib tosylate and hydroxychloroquine sulfate work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine sulfate may increase the effectiveness of sorafenib tosylate. Giving sorafenib tosylate and hydroxychloroquine may work better in treating patients with liver cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Sorafenib Tosylate, Bavituximab, and Stereotactic Body Radiation Therapy as First Line Therapy in Treating Patients with Advanced Liver Cancer That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with sorafenib tosylate and bavituximab as first line therapy in treating patients with liver cancer that has spread to other places in the body and cannot be removed by surgery. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bavituximab, interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving sorafenib tosylate, bavituximab, and stereotactic body radiation therapy as first line therapy may work better in treating patients with liver cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and / or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

    A two part study to determine the maximum tolerated dose and / or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line. There will be a dose escalation part and a dose expansion part.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

    This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia (AML). It also evaluates safety and potential efficacy. Kinase inhibitor is a type of substance that blocks an enzyme called a kinase. Human cells have many different kinase enzymes, and they help control important cell functions. Certain kinases are more active in some types of cancer cells and blocking them may help keep the cancer cells from growing. Testing samples of blood from patients with AML in the laboratory with kinase inhibitors may help determine which kinase inhibitor has more activity against cancer cells and which one should be combined with standard of care chemotherapy. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a personalized kinase inhibitor therapy combined with standard chemotherapy may be a better treatment for AML.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Sorafenib Tosylate and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors

    This phase II trial studies how well sorafenib tosylate and irinotecan hydrochloride work in treating pediatric patients with solid tumors that have returned after a period of improvement or have not responded to previous treatment. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sorafenib tosylate and irinotecan hydrochloride may work better in treating pediatric patients with recurrent or refractory solid tumors.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri


1 2 Next >